Featured Publications
Trends in Racial and Ethnic Disparities in Barriers to Timely Medical Care Among Adults in the US, 1999 to 2018
Caraballo C, Ndumele CD, Roy B, Lu Y, Riley C, Herrin J, Krumholz HM. Trends in Racial and Ethnic Disparities in Barriers to Timely Medical Care Among Adults in the US, 1999 to 2018. JAMA Health Forum 2022, 3: e223856. PMID: 36306118, PMCID: PMC9617175, DOI: 10.1001/jamahealthforum.2022.3856.Peer-Reviewed Original ResearchConceptsTimely medical careSerial cross-sectional studyNational Health Interview SurveyCross-sectional studyHealth Interview SurveyMedical careLack of transportationEthnic disparitiesHispanics/LatinosWhite individualsEthnicity groupsInterview SurveyCost of careSelf-reported raceStudy cohortClinic hoursMAIN OUTCOMEMedical officesCarePrevalenceLatino individualsBlack individualsSignificant differencesSignificant increasePopulation groupsIdentifying high-value care for Medicare beneficiaries: a cross-sectional study of acute care hospitals in the USA
Herrin J, Yu H, Venkatesh AK, Desai SM, Thiel CL, Lin Z, Bernheim SM, Horwitz LI. Identifying high-value care for Medicare beneficiaries: a cross-sectional study of acute care hospitals in the USA. BMJ Open 2022, 12: e053629. PMID: 35361641, PMCID: PMC8971780, DOI: 10.1136/bmjopen-2021-053629.Peer-Reviewed Original ResearchConceptsAcute care hospitalsHigh-value careStar hospitalsCare hospitalMedicare spendingEligible Medicare patientsRetrospective observational studyCross-sectional studyNon-teaching statusHigh-quality careHigh-quality hospitalsLow-cost hospitalsHigh-cost hospitalsCharacteristics of hospitalsValue of careSecondary outcomesPrimary outcomeMedicare patientsObservational studyMedicare beneficiariesHospitalQuality careOverall star ratingHospital ValueComparative Effectiveness of Machine Learning Approaches for Predicting Gastrointestinal Bleeds in Patients Receiving Antithrombotic Treatment
Herrin J, Abraham NS, Yao X, Noseworthy PA, Inselman J, Shah ND, Ngufor C. Comparative Effectiveness of Machine Learning Approaches for Predicting Gastrointestinal Bleeds in Patients Receiving Antithrombotic Treatment. JAMA Network Open 2021, 4: e2110703. PMID: 34019087, PMCID: PMC8140376, DOI: 10.1001/jamanetworkopen.2021.10703.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAnticoagulantsAntifibrinolytic AgentsAtrial FibrillationClinical Decision-MakingCohort StudiesCross-Sectional StudiesFemaleFibrinolytic AgentsGastrointestinal HemorrhageHumansMachine LearningMaleMiddle AgedMyocardial IschemiaPredictive Value of TestsRetrospective StudiesRisk AssessmentThienopyridinesUnited StatesVenous ThromboembolismYoung AdultConceptsGastrointestinal bleedingIschemic heart diseaseCross-sectional studyThienopyridine antiplatelet agentAntithrombotic treatmentVenous thromboembolismAntiplatelet agentsRandom survival forestStudy cohortAtrial fibrillationValidation cohortHeart diseaseHAS-BLED risk scoreRetrospective cross-sectional studyCox proportional hazards regressionHAS-BLED scorePrior GI bleedPatients 18 yearsCohort of patientsEntire study cohortProportional hazards regressionOptumLabs Data WarehouseMedicare Advantage enrolleesPositive predictive valueRisk prediction modelPopulation well-being and electoral shifts
Herrin J, Witters D, Roy B, Riley C, Liu D, Krumholz HM. Population well-being and electoral shifts. PLOS ONE 2018, 13: e0193401. PMID: 29529049, PMCID: PMC5846778, DOI: 10.1371/journal.pone.0193401.Peer-Reviewed Original Research
2024
Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk
Neumiller J, Herrin J, Swarna K, Polley E, Galindo R, Umpierrez G, Deng Y, Ross J, Mickelson M, McCoy R. Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk. Clinical Journal Of The American Society Of Nephrology 2024 DOI: 10.2215/cjn.0000000587.Peer-Reviewed Original ResearchSodium-glucose co-transporter 2 inhibitorsGlucagon-like peptide-1 receptor agonistsSodium-glucose co-transporter 2Dipeptidyl peptidase-4 inhibitorsGlucagon-like peptide-1Dipeptidyl peptidase-4Receptor agonistsPrimary composite outcomeKidney replacement therapyChronic kidney diseaseComposite outcomeSecondary composite outcomeType 2 diabetesGLP-1 receptor agonist therapyCVD riskCardiovascular diseaseModerate CVD riskPrescribed glucose-lowering agentsBaseline CVD riskHigh-risk patientsAssociated with risk reductionCKD stage 3Retrospective observational studyGlucose-lowering agentsModerate cardiovascular riskRisk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk
McCoy R, Swarna K, Neumiller J, Polley E, Deng Y, Mickelson M, Herrin J. Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Clinical Diabetes 2024 DOI: 10.2337/cd24-0007.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2Moderate cardiovascular disease riskRisk of severe hypoglycemiaGlucose-lowering therapyCardiovascular disease riskType 2 diabetesSevere hypoglycemiaSodium-glucose cotransporter 2 inhibitorsDPP-4GLP-1 receptor agonistsGlucagon-like peptide 1Risk of hypoglycemiaDPP-4 inhibitorsDipeptidyl peptidase 4Disease riskAvoidance of hypoglycemiaSulfonylurea therapyReceptor agonistsCotransporter 2Sulfonylurea usePatient populationGLP-1Peptidase 4HypoglycemiaEmergency departmentInternal tremors and vibrations in long COVID: a cross-sectional study
Zhou T, Sawano M, Arun A, Caraballo C, Michelsen T, McAlpine L, Bhattacharjee B, Lu Y, Khera R, Huang C, Warner F, Herrin J, Iwasaki A, Krumholz H. Internal tremors and vibrations in long COVID: a cross-sectional study. The American Journal Of Medicine 2024 PMID: 39069199, DOI: 10.1016/j.amjmed.2024.07.008.Peer-Reviewed Original ResearchNew-onset conditionsInternal tremorLong COVID symptomsCOVID symptomsNon-Hispanic whitesCross-sectional studyQuality of lifeVisual analogue scaleWorse healthHealth statusStudy participantsDemographic characteristicsAnalogue scaleOutcome variablesNeurological conditionsLong COVIDMast cell disordersTreatment experienceHealthComorbiditiesSymptomsMedian agePeopleCell disordersLearning implementation of a guideline based decision support system to improve hypertension treatment in primary care in China: pragmatic cluster randomised controlled trial
Song J, Wang X, Wang B, Ge Y, Bi L, Jing F, Jin H, Li T, Gu B, Wang L, Hao J, Zhao Y, Liu J, Zhang H, Li X, Li J, Ma W, Wang J, Normand S, Herrin J, Armitage J, Krumholz H, Zheng X. Learning implementation of a guideline based decision support system to improve hypertension treatment in primary care in China: pragmatic cluster randomised controlled trial. The BMJ 2024, 386: e079143. PMID: 39043397, PMCID: PMC11265211, DOI: 10.1136/bmj-2023-079143.Peer-Reviewed Original ResearchConceptsClinical decision support systemsPrimary care practicesElectronic health recordsIntervention groupSystolic blood pressurePrimary careCare practicesBlood pressure <Health recordsPragmatic cluster randomised controlled trialCluster randomised controlled trialImproving hypertension treatmentPrimary care settingBlood pressure control ratesBlood pressureProportion of visitsProportion of participantsRandomised controlled trialsSystolic blood pressure <Control groupInjurious fallsRelated visitsCare settingsDiastolic blood pressure <Follow-upBridging clinical informatics and implementation science to improve cancer symptom management in ambulatory oncology practices: experiences from the IMPACT consortium
McCleary N, Merle J, Richardson J, Bass M, Garcia S, Cheville A, Mitchell S, Jensen R, Minteer S, Austin J, Tesch N, DiMartino L, Hassett M, Osarogiagbon R, Wong S, Schrag D, Cella D, Smith A, Smith J, Cella D, Cheville A, Hassett M, Osarogiagbon R, Schrag D, Wong S, Kroner B, Smith A, DiMartino L, Garcia S, Griffin J, Jensen R, Mitchell S, Ruddy K, Smith J, Yanez B, Bian J, Dizon D, Hazard-Jenkins H, Ardini M, Ahrens P, Austin J, Barrett F, Bass M, Begnoche M, Cahue S, Caron K, Chlan L, Coughlin A, Cronin C, Dias S, Faris N, Flores A, Garcia M, Hemming K, Herrin J, Hodgdon C, Kircher S, Kroenke K, Lam V, Lancki N, H Q, Mallow J, McCleary N, Norton W, O'Connor M, Pachman D, Pearson L, Penedo F, Podratz J, Popovic J, Preiss L, Rahman P, Redmond S, Reich J, Richardson J, Richardson K, Ridgeway J, Rutten L, Schaepe K, Scholtens D, Poirier-Shelton T, Silberman P, Simpson J, Tasker L, Tesch N, Tofthagen C, Tramontano A, Tyndall B, Uno H, Wehbe F, Weiner B. Bridging clinical informatics and implementation science to improve cancer symptom management in ambulatory oncology practices: experiences from the IMPACT consortium. JAMIA Open 2024, 7: ooae081. PMID: 39234146, PMCID: PMC11373565, DOI: 10.1093/jamiaopen/ooae081.Peer-Reviewed Original ResearchElectronic patient-reported outcomesElectronic health recordsClinical informaticsImplementation scienceImplementation of electronic patient-reported outcomesElectronic health record designElectronic health record systemsImplementation strategiesCancer symptom managementSystematic symptom assessmentAmbulatory oncology settingAmbulatory oncology practicesManagement of symptomsPatient-reported outcomesEHR functionsEPRO dataCancer symptomsSymptom managementIS researchHealth recordsImplementation scientistsPragmatic trialOncology settingInformatics implementationSymptom assessment413-P: Comparative Effectiveness of Glucose-Lowering Agents on Kidney Outcomes in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk
NEUMILLER J, HERRIN J, SWARNA K, POLLEY E, GALINDO R, UMPIERREZ G, DENG Y, MICKELSON M, MCCOY R. 413-P: Comparative Effectiveness of Glucose-Lowering Agents on Kidney Outcomes in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk. Diabetes 2024, 73 DOI: 10.2337/db24-413-p.Peer-Reviewed Original ResearchPatient-Centered Outcomes Research InstituteModerate CVD riskKidney composite outcomeAssociated with lower riskGLP-1RACVD riskType 2 diabetesKidney outcomesComposite outcomeKidney diseaseLow riskHigh riskInitiation of kidney replacement therapyEffects of glucose-lowering agentsCardiovascular diseaseHigh risk of cardiovascular diseaseAssociated with increased riskBaseline CVD riskAssociated with higher riskRisk of cardiovascular diseaseGlucose-lowering agentsCare of peopleIncident kidney diseaseModerate cardiovascular riskTarget trial frameworkPrimary outcomes of the enhanced, EHR-facilitated cancer symptom control (E2C2) cluster-randomized, stepped wedge, pragmatic trial.
Cheville A, Pachman D, Kroenke K, Herrin J, Grzegorczyk V, Mitchell S, Griffin J, Ridgeway J, Austin J, Smith A, Chlan L, Tofthagen C, Ruddy K. Primary outcomes of the enhanced, EHR-facilitated cancer symptom control (E2C2) cluster-randomized, stepped wedge, pragmatic trial. Journal Of Clinical Oncology 2024, 42: lba12006-lba12006. DOI: 10.1200/jco.2024.42.17_suppl.lba12006.Peer-Reviewed Original ResearchElectronic patient-reported outcome measuresCollaborative care modelElectronic health recordsNumerical rating scaleCluster-randomizedPragmatic trialSymptom burdenAssociated with adverse health outcomesCCM-based interventionsPatient-reported outcome measuresHealth service outcomesSelf-management informationClinician decision supportPrimary outcomeCancer type or stageMulti-state health systemCancer symptom controlCluster randomized trialMedical oncology clinicAdverse health outcomesUsual careCare modelCare teamSymptom managementSymptom scoresSPPADE symptom prevalence and severity in a diverse sample of patients living with metastatic cancers.
Pachman D, Ruddy K, Grzegorczyk V, Kroenke K, Griffin J, Ridgeway J, Chlan L, Tofthagen C, Leventakos K, Strand J, Austin J, Smith A, Mitchell S, Herrin J, Cheville A. SPPADE symptom prevalence and severity in a diverse sample of patients living with metastatic cancers. Journal Of Clinical Oncology 2024, 42: 11108-11108. DOI: 10.1200/jco.2024.42.16_suppl.11108.Peer-Reviewed Original ResearchSymptom burdenHigh school educationDiverse sample of patientsAmerican Indian/Alaska Native (AI/ANSymptom management interventionsHigh symptom burdenPhysical function impairmentComposite scoreCancer symptom controlTotal symptom burdenSchool educationComposite mean scoresSymptom interventionMetastatic diseaseMetastatic cancerSymptom prevalenceSample of patientsSymptom surveyEmployment statusDisability statusMean scoreICD codesCancer typesManagement interventionsSymptom controlComparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy
Barkmeier A, Herrin J, Swarna K, Deng Y, Polley E, Umpierrez G, Galindo R, Ross J, Mickelson M, McCoy R. Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy. Ophthalmology Retina 2024, 8: 943-952. PMID: 38735641, DOI: 10.1016/j.oret.2024.05.003.Peer-Reviewed Original ResearchThe PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID
Krumholz H, Sawano M, Bhattacharjee B, Caraballo C, Khera R, Li S, Herrin J, Coppi A, Holub J, Henriquez Y, Johnson M, Goddard T, Rocco E, Hummel A, Al Mouslmani M, Putrino D, Carr K, Carvajal-Gonzalez S, Charnas L, De Jesus M, Ziegler F, Iwasaki A. The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID. The American Journal Of Medicine 2024 PMID: 38735354, DOI: 10.1016/j.amjmed.2024.04.030.Peer-Reviewed Original ResearchLC trialPROMIS-29Participants' homesTargeting viral persistencePlacebo-controlled trialDouble-blind studyElectronic health recordsCore Outcome MeasuresLong COVIDEQ-5D-5LRepeated measures analysisEvidence-based treatmentsPhase 2Double-blindParticipant-centred approachStudy drugPrimary endpointSecondary endpointsCommunity-dwellingHealth recordsHealthcare utilizationContiguous US statesViral persistencePatient groupDrug treatmentCalculation of Overall Hospital Quality Star Ratings With and Without Inclusion of the Peer Grouping Step
Gettel C, Bagshaw K, Qin L, Lin Z, Rothenberg E, Omotosho P, Goutos D, Herrin J, Suter L, Schreiber M, Fleisher L, Myers R, Spivack S, Venkatesh A. Calculation of Overall Hospital Quality Star Ratings With and Without Inclusion of the Peer Grouping Step. JAMA Network Open 2024, 7: e2411933. PMID: 38753326, PMCID: PMC11099678, DOI: 10.1001/jamanetworkopen.2024.11933.Peer-Reviewed Original ResearchConceptsCenters for Medicare & Medicaid ServicesCross-sectional studyHospital characteristicsHigher star ratingsStar ratingsOverall hospital qualityLowest-performing hospitalsOverall star ratingQuality star ratingsHospital star ratingsStar Ratings scoresHospital qualityHospital performanceStratified hospitalsMedicaid ServicesMain OutcomesFace validityPeer groupPeer group approachPrimary outcomePeer comparisonHospitalRating scoresPeerMeasurement groupLong COVID Characteristics and Experience: A Descriptive Study from the Yale LISTEN Research Cohort
Sawano M, Wu Y, Shah R, Zhou T, Arun A, Khosla P, Kaleem S, Vashist A, Bhattacharjee B, Ding Q, Lu Y, Caraballo C, Warner F, Huang C, Herrin J, Putrino D, Michelsen T, Fisher L, Adinig C, Iwasaki A, Krumholz H. Long COVID Characteristics and Experience: A Descriptive Study from the Yale LISTEN Research Cohort. The American Journal Of Medicine 2024 PMID: 38663793, DOI: 10.1016/j.amjmed.2024.04.015.Peer-Reviewed Original ResearchExperiences of peopleHealth statusLong COVIDLower health statusNew-onset conditionsCommunity support servicesNon-Hispanic whitesArray of healthQuality of lifeVisual analogue scaleMental healthPsychological distressPsychological statusDescriptive studyHealthcare systemMedian scoreSupport servicesResearch cohortSocial isolationDemographic characteristicsAnalogue scaleImpact of long COVIDHealthFinancial stressParticipants1087 Recognizing Sleep Disorders in the US Military Health System: Differences Between On-base and Private Sector Care
Capaldi V, Williams S, Thomas C, Herrin J, Hong A, Funk W, Collen J, Stryckman B, Albrecht J, Wickwire E. 1087 Recognizing Sleep Disorders in the US Military Health System: Differences Between On-base and Private Sector Care. Sleep 2024, 47: a467-a467. DOI: 10.1093/sleep/zsae067.01087.Peer-Reviewed Original ResearchObstructive sleep apneaMilitary Data RepositoryMilitary Health System beneficiariesSleep disordersMilitary Health SystemBetween-group differencesUS Military Health SystemSleep carePsychiatric comorbiditiesPrivate sector careRecognize sleep disordersComorbid sleep disordersICD-10 diagnostic codesSleep apneaClinical characteristicsDiagnosis of insomniaDiagnostic codesBetween-groupDirect careComorbiditiesInsomniaDisordersSleepICD-10Active duty personnelEffectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
McCoy R, Herrin J, Swarna K, Deng Y, Kent D, Ross J, Umpierrez G, Galindo R, Crown W, Borah B, Montori V, Brito J, Neumiller J, Mickelson M, Polley E. Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk. Nature Cardiovascular Research 2024, 3: 431-440. PMID: 38846711, PMCID: PMC11156225, DOI: 10.1038/s44161-024-00453-9.Peer-Reviewed Original ResearchAdverse cardiovascular eventsGlucose-lowering medicationsType 2 diabetesCardiovascular diseaseGLP-1RACardiovascular eventsGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsRetrospective cohort studyCardiovascular disease risk reductionGlucose-lowering agentsModerate cardiovascular riskCardiovascular risk reductionReceptor agonistsEffects of glucose-lowering medicationsRisk reductionCardiovascular riskCohort studyCardiovascular outcomesHigh riskBaseline riskModerate riskEnrollment in High-Deductible Health Plans and Incident Diabetes Complications
McCoy R, Swarna K, Jiang D, Van Houten H, Chen J, Davis E, Herrin J. Enrollment in High-Deductible Health Plans and Incident Diabetes Complications. JAMA Network Open 2024, 7: e243394. PMID: 38517436, PMCID: PMC10960199, DOI: 10.1001/jamanetworkopen.2024.3394.Peer-Reviewed Original ResearchConceptsHigh-deductible health plansHealth plansChronic disease managementOdds of myocardial infarctionLower-extremity complicationsMixed-effects logistic regression modelsOut-of-pocket costsAssociated with increased oddsDiabetic complicationsInverse propensity score weightingLogistic regression modelsCardiovascular risk factorsEmployer-sponsored health plansDiabetes careRetrospective cohort studyUS adultsPropensity score weightingPotential selection biasMain OutcomesCohort studyBaseline yearIncident complicationsDisease managementMixed-effectsPotential harmDisparities in Acute and Chronic Complications of Diabetes Along the U.S. Rural-Urban Continuum.
Steiger K, Herrin J, Swarna K, Davis E, McCoy R. Disparities in Acute and Chronic Complications of Diabetes Along the U.S. Rural-Urban Continuum. Diabetes Care 2024, 47: 818-825. PMID: 38387066, PMCID: PMC11043221, DOI: 10.2337/dc23-1552.Peer-Reviewed Original ResearchResidents of remote areasRural-urban continuumHazard ratioLower-extremity complicationsHazard of myocardial infarctionMedicare Advantage beneficiariesRemote areasHazard of strokeOptumLabs Data WarehouseComplications of diabetesLower hazardMyocardial infarctionRetrospective cohort studyHeart failureDiabetic complicationsCohort studyResidents of small townsEnd-stage kidney diseaseSmall townsChronic complications of diabetesChronic diabetic complicationsResidentsDiabetesDisparitiesChronic complications